版本:
中国

BRIEF-Biogen licenses Phase 2 Anti-Tau antibody from Bristol-Myers Squibb

April 13 Biogen Inc:

* Biogen Inc - under agreement, biogen will receive worldwide rights to BMS-986168

* Biogen Inc - Biogen will be responsible for full development and global commercialization of bms-986168 in ad and psp

* Biogen Inc - to assume all remaining obligations to former stockholders of Ipierian, Inc related to Bristol-Myers Squibb's acquisition of company in 2014

* Biogen Inc - may pay up to $550 million in remaining milestones plus royalties including a near term $60 million milestone

* Biogen Inc - announced an agreement to exclusively license BMS-986168 from Bristol-Myers Squibb Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐